Literature DB >> 27643848

Idarucizumab for dabigatran reversal - Does one dose fit all?

Amihai Rottenstreich1, Nivin Jahshan2, Limor Avraham2, Yosef Kalish3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27643848     DOI： 10.1016/j.thromres.2016.09.006

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  4 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".

Authors:  Kirollos S Kamel; Paul K L Chin; Matthew P Doogue; Murray L Barclay
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

3.  Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

Authors:  Nicolas Gendron; Juliette Gay; Marine Lemoine; Pascale Gaussem; Agnès Lillo-Le-Louet; David M Smadja
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

Review 4.  Perioperative management of patients on direct oral anticoagulants.

Authors:  Virginie Dubois; Anne-Sophie Dincq; François Mullier; Sarah Lessire; Jonathan Douxfils; Brigitte Ickx; Charles-Marc Samama; Jean-Michel Dogné; Maximilien Gourdin; Bernard Chatelain
Journal:  Thromb J       Date:  2017-05-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.